<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 351 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page350.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=351">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 351 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 351</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=351"><img src="../thumb/351.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>314 / 2020-04                                                           Endocrine System - 19.8
   (S4) TABS, 42/21.12/0121, 0122  constip., dyspeps., inj. site urticar., microlithias., bil.colic, hepat.ste-  Indications: Early & advanc.breast Ca in postmenopaus.women.
   714015-001: 30 mg, 28, R1 589,20  atos., contus., proced.naus., hypercholesterolaem., hyperlipidaem.,   Effic.not demonstrat.in oestrog.recept.negat.pts.unless prev.posit.
   714016-001: 60 mg, 28, R3 178,40  hypertriglyceridaem., polydips., musc. weakn., migraine, syncope,   clinic. respons.to tamoxifen report.
   Dosage: Admin.with food. Take whole, do not div.  trem., polyur., rash, urticar., hyperhidros., flush., haematoma, hyper-  (S4) TABS. 42/21.12/0260
   Second.hyperparathyroid: Adults & elderly &gt;65 yrs: Recomm.  tens., Potent: pancreatit.  715720-001: 1 mg, 30, R215,16
   start.dos: 30 mg once per day. Titrat.every 2-4 wks.to max.dos.of   Warnings and special precautions: Effic.not demonstrat.for   Dosage: 1 tab.once dly.
   180 mg once dly.to achieve target parathyroid horm of between   more than 1 yr., monit.for S&S of hypocortisol. admin.tempor.exo-  Contraindications: Safety & effic.in pre-menopaus. women &
   150-300 pg/ml in dialys.pts. Assess lev.12 hrs.aft. dos. Meas.PTH   gen.ster.replacem. ther/ dos.reduct.as necess., hyperglycaem.high.  childr.not est., sev.ren. impairm., pregn.& lactat., mod.to sev.hepat.
   1-4 wks.aft.init./dos.adjustm.& every 1-3 mnths.dur.maint. Monit.  in pts.with pre-diabet.condit./est.diab.mellit.& manag. with appropr.  dis., concom.tamoxifen &/oestrog.contain.ther.
   ser.Ca lev.freq. dur.dos titrat./within 1 wk.of init./dos.adjustm.&   antidiabet.ther., assess glycaem. status bef.start./dur.& aft.discont.   Side effects: Leucopen., allerg.reacts.incl.angio-oed.& anaphy-
                                                st
   mnthly once maint.dos.est.   treatm., bld.gluc.self monit.wkly.dur.1  2-3 mnths thereaft. as clinic.  lax., urticar., hot flush., oed., thrombophlebit., hepato-bil.disords.,
   Parathyroid Carcinoma: Adults & elderly &gt;65 yrs: Recomm.   appropr., discont.or reduc.dos.if uncontroll.hyperglycaem.persists,   joint pain/ stiffn., myalg., arthralg., asthen., fev., flu-like syndr.,
   start.dos: 30 mg twice per day. Titrat. every 2-4 wks.through sequent.  poor glycaem. control. incr.pt.risk of ser.hyperglycaem.& assoc.   vag.dryn./bleed, hair thin., rash, erythem. multiforme, Stev.Johns.
   dos.of 30 mg 2xdly, 60 mg 2xdly., 90 mg 2xdly.& 90 mg 3-4xdly.as   complicat., monit.card.dis.& bradycard. risk fact., pts.at signific.risk   syndr., GI disturbs., headache, carpal.tunnel syndr., dizzin., drowsin.,
   necess.to reduc.ser.Ca conc.to bel.upper limit of norm. Max.dos.in   of develop. QT prolongat., baseline ECG recomm.bef.init.ther.& as   somnol., anorex., hypercholesterolaem., low. circulat. oestrog.lev.
   clinic.trails: 90 mg 4xdly. Meas. ser.Ca within 1 wk.aft.init./dos.ad-  clinic. necess., correct hypokalaem./-magnesaem.prior to admin.&   Special precautions: Poss.bone miner.densit. reduct.with incr.
   justm.& every 2-3 mnths.once maint.lev.est.  monit.dur.ther., concom.anti-dysrhythm. meds./ other meds that may   fract.risk, biochem.confirmat.of menopause if in doubt., lact.intol.pts.
   Contra-indications: Safety & effic.in pts.bel.18 yrs. not est.  prolong QT interv., monit. liv.funct.aft.first 2-3 wks.& then mnthly.x3   Drug interactions: Dimin.pharmacolog.act.with Tamoxifen &/
   Side-effects:. N&V, hypersens.reacts., anorex., dizzin., paraes-  mnths., discont.if pt.develops jaund./sustain.incr.in AST/ALT, ultra-  other oestrog.contain.ther.
   thes., seiz., dyspeps., rash, myalg., asthen., hypocalcaem., reduc.  son.gallbladd.examinat.bef.& at 6-12 mnthly interv.dur.ther., monit.  TAMOPLEX, (Cipla Medpro) Teva
   testosterone lev.            pituit.funct., meds. possess.low therapeut.index metabol.main. by
   Special precautions: Seiz.thresh.lowered by signific. ser.Ca lev.  CYP3A4, reproduct.toxic.in anim.stud., excret.in milk of rats, effs.on   Tamoxifen.
                                                              Indications: Palliat.treatm.of oestrog.depend advanc.breast ad-
   reduct., do not init.ther.where ser.Ca bel.low.limit.of norm.range,   female reproduct.paramet. shown, mod.hepat.impairm., no clinic.
   monit.for hypocalcaem., if hypocalcaem.evid.raise ser.Ca through   data in pts.und.18 yrs.  enocarcinoma in post-menopaus. women, other tumours contain.
                                                              oestrog.receptors
   Ca-contain.phosph,bind./vit.D sterols and/or diaslys.fluid Ca conc.  Interactions: Ciclosporin bioavail.decr., poss. indir.eff.in decr.
   adjustm., reduc.dos. /discont.if hypocalcaem.persists, reduc.dos./   metabol.clear.of cmpds.metabol.by CYP450 enzymes, poss.incr.  (S4) TABS. 34/21.12/0067.
                                                              712610-001: 20 mg, 30, R124,16
   discont.if PTH lev.decr.bel.recomm.target, mod.to sev.hepat.im-  availabil.of bromocriptine  712610-002: 20 mg, 250, R1 034,67
   pairm., use in pregn.only if potent. benef.justif.potent.foet.risk,   See also MDR page 573.
   excret.in lactat.rats milk   SOMATULINE AUTOGEL, Sanofi-Aventis [P/S]  Dosage: 20-40 mg dly in 2 div.dos. Respons.usual within 4-10 wks.
                                                              but poss.delay.in pres.of metastas.
   Drug interactions: Incr.lev.with concom.strong CYP3A4 inhibit.,   Lanreotide.
   poss.dos.adjustm.with strong CYP3A4 induc./strong CYP1A2 in-  Indications: Acromeg.when secret.of GH & IGF-1 remain abnorm.  Contraindications: Pregn., safety in lactat.not est., women
                                                              with funct.ovar.,
   hibit.& meds. metabol.predom.by CYP2D6 enzyme, clear.high.
   in smokers.                  aft.surg.&/ radiother., clin.sympts. assoc.with acromeg., clin.sympts.  Side effects: Hot flush., oed., vag.bleed./ discharge, prurit.vulv.,
                                of carcin.tumors.
                                                              GI disturbs., lightheadedn., skin rash, hypercalcaem., tumour pain,
   See also MDR page 151.
                                (S4) SOL.FOR INJ. 45/21.12/1022, 1023, 1024.  trans. thrombocytopen.& leucopen., headache, depress., fatig.,
   SIGNIFOR, Novartis [P/S] &   720985-001: 60 mg, 1xpre-fill.syr., R17 903,40  confus., hepatotox., leg cramps, alopec., dry skin, thromboembol.,
   Pasireotide                  720986-001: 90 mg, 1xpre-fill.syr, R26 855,09  pulm.embol., alt.bld.lipids, menstr.suppress., cyst.ovar.swell.in pre-
         nd
   Indications: 2  line acromegaly ther.aft.pituit. surg./when surg not   720987-001: 120 mg, 1xpre-fill.syr, R35 806,80  menopaus. women, trans. fall in platel.counts, vis.disturbs., corn.
   feasible in pts.respond. inadeq. to other somatostat.analog.or where   Dosage: Inj.deep SC in super.extern.quadr.of buttock. Altern.inj.  changes, cataracts and/or retinopathy.
   other SSA’s cannot be used   site betw.left&right side.    Special precautions: Concom.anticoag.dos. reduct.& caref.monit.
   (S4) LA POWD.FOR SUSP.FOR INJ, 49/32/0272, 0273, 0274  Acromegaly: Recomm.start.dos.: 90 mg every 28 days x 3 mnths.   recomm., vag.bleed.to be investigat., galact.intol.
   723642-001: 20 mg/2 ml, 1x2 ml, R35 154,28  Thereaft.adjust.treatm.for each pt.in a specialis.unit. Indiv.dos.ac-  Drug interactions: Concomm.coumar.anticoags. incr.anticoag.
   723644-001: 40 mg/2 ml, 1x2 ml, R39 078,59  cord.to response which is evaluat.by monitor.plasma GH & IGF-1   eff.with poss.bleed.risk.
   723645-001: 60 mg/2 ml, 1x2 ml, R43 420,,62  levels & by assess.changes in sympts.
   Dosage: Init.recomm.dos: 40 mg deep IMI every 4 wks. May be incr.  Recommend: Reduc.dos.when conc.are normalis. (GH &lt; 1 ng/ml   TAMOXIHEXAL, Sandoz
                                                              Tamoxifen citrate
   to max.60 mg where GH&/IGF-1 lev.not fully control.aft.3 mnths.ther.   & normalis. IGF-1 &/ disappear.of clinic.sympts.), maint.dos.when
   Decr.dos. tempor./perman.by 20 mg decrem.  conc.of GH betw. 2,5 ng/ml - 1 ng/ml, incr. dos. when GH conc. &gt;   Indications: Breast Ca.
                                                              (S4) TABS, 33/21.12/.0518
   Contraindications: Sev.hepat.impairm.(Child Pugh C).  2,5 ng/ml. Treat.pts.well controll.on somatostat. analog. with So-  710403-001: 20 mg, 30, R142,71
   Side effects: V.common: Diarrh., cholelithias., hyperglycaem.,   matuline autogel 120 mg every 42 or 56 days.  Dosage: Adults incl elderly: 20-40 mg in div.dos 2xdly or as
   diab.mellit., abdom.pain, alopec. Common: Anaem., adren.in-  Carcin.tumours: Recommend.start.dos: 90 mg every 28 days   sngl.once dly.dos.
   suffic., type 2 diab. melllit., imp.gluc.tol., dizzin., headache, sinus   dur. 2 mnths. Adj.dos.accord.to degr. of symptomat.relief obtain.   Contraindications: Pregn., not recomm.in lactat., safety & ef-
   bardycard., QT prolongat., abdom.distens., naus., inj.site reacts.   In case of insuffic. response dos.may be incr.to 120 mg every 28   fic.in childr.not est.
   Potent: pancreatit.          days (4 weeks). If response suffic.dos.may be decr.to 60 mg every
   Warnings and special precautions: Assess glycaem.status   28 days (4 weeks).  Side effects: Pancreatit., endometr.chang incl. hyperplas./ polyps
                                                              & Ca, second.prim.tumours, hot flush., vag.bleed.& discharg., prurit.
   bef.start./dur.& aft.discont.treatm., bld.gluc. self monit.wkly.dur.1   st  Ren/hepat.impairm: Recommend.start.dos: 60 mg at 4 wk.   vulv., GI effs., tumour flare, lightheadedn., fatig., weight gain, fluid
   3 mnths thereaft. as clinic.appropr.& for 1st 4-6 wks.aft.any dos.   interval.x 3 mnths., follow.by dos. adjustm.as describ.above.  retent., alopec., menstr.suppress., cystic ovar. swell.in premenopaus.
   change, init./adjust anti-diabet.treatm.if hyperglycaem. develops   Contraindications: Complicat.untreat.lithias.of bile ducts, pregn.&   women, uter.fibroids, bld. dyscras., leucopen., thrombolyt.events incl.
   dur treatm., discont.or reduc. dos.if uncontroll.hyperglycaem.per-  lactat., no exper.in childr.  DVT pulm. embol., skin rash incl.erythem.multiforme & Stev.John.
   sists, poor glycaem.control.incr.pt.risk of ser. hyperglycaem.& as-  Side effects: Diarrh., abdom.pain., naus., hyperglycaem., abnorm.  syndr., hypercalcaem.in pts.with bony metastas., vis.disturbs. incl.
   soc.complicat., monit.card.dis.& bradycard. risk fact., pts.at sig-  gluc.tol., headache, constipat., flatul., tenesmus, vomit., chole-  corn.chang./cataracts & retinopathy, elev.liv.enzymes, cholestas.,
   nific.risk of develop. QT prolongat., baseline ECG recomm.bef.init.   lithias., gall. bladd.sludge, incr.bilirub., prurit., fatig., asthen., skin   hepatit., hypersens.reacts.
   ther.& 21 days aft. init.ther., correct hypokalaem./-magnesaem.   nodule, inj.site pain/reacts., hot flush., somnol., leg pain, decr.li-  Special precautions: Caref.exam.in pre-menopaus. pts.bef.init.
   prior to admin.& monit.dur.ther., concom. anti-dysrhythm.meds./  bido, incr.sweat., malais.  ther.to excl.pregn., concom. coumar. anticoags., spontan.abort./foet.
   other meds that may prolong QT interv., monit.liv.funct.aft.first 2-3   Warnings and special precautions: Potent. trans. inhibit.of   deaths./ birth defects report.if used dur.pregn., avoid pregn. while
   wks.& then mnthly.x3 mnths., discont.if pt. develops jaund./sus-  insul.& glucag.secret., monit.bld. gluc. lev.in diabet.pts., gall blad.  on ther./within 2 mnths.of cessat., pancreatit. most.observ.with pre-
   tain.incr.in AST/ALT, ultrason. gallbladd. examinat.bef.& at 6-12   motil.poss.reduc., gall blad.echography advis.in pts who have not   treatm.elev. triglycerid., investig.vag.bleed., occur.of second. prim.
   mnthly interv. dur. ther., monit.pituit.funct., monit.for S&S of hypo-  underg. cholecystect., tot.clearance decr.approx.2-fold.& half-life/  tumours at sites other then endometr.& opp. breast., reduc.dos.if
   cortisol. admin.tempor.exogen.ster. replacem. ther/ dos.reduct.as   AUC conseq.incr.in sev.ren. impairm, incr.vol.of distribut.& mean   S/E sev.& stop treatm.if no respons.
   necess., reproduct.toxic.in anim.stud., excret.in milk of rats, effs.on   resid.time, without any tot.clear./AUC modificat.in hepat. impairm.,   Drug interactions: Anticoag.eff.of coumar. anticoag. incr., incr.risk
   female reproduct.paramet.shown, mod.hepat.impairm., no clinic.  incr.half-life & mean resid.time in elderly.  of thrombo-embol.events in combinat.with cytotox.
   data in pts.und.18 yrs.,     Drug interactions: Bld.lev.of concom.ciclospor. reduc., cocom.insul.
   Interactions: Ciclosporin bioavail.decr.  may cause hypoglycaemia.  TASDIAM, (Eurolab) Ranbaxy [P/S]
   (S4) SOL.FOR INJ, 48/34/0489, 0490, 0491  STRADEXA, Eurolab  Bicalutamide.
   Indications: Cushings dis.where pituit.surg.not an option/has   Anastrozole.  Indications: Loc.advanc.prostate Ca alone or as adjunct.to surg./
   not been curativ                                           radiother., monother.in non-metast. prostate Ca where surg./med.
   3000004-001: 0,3 mg/ml, 60x1 ml, R35 168,62                castrat.not appropr.
   3000005-001: 0,6 mg/ml, 60x1 ml, R40 795,53                (S4) FILM-COAT.TABS. 44/21.12/1023
   3000006-001: 0,9 mg/ml, 60x1 ml, R47 322,85  Medicines should   722149-001: 150 mg, 30, R2 632,58
   Dosage: Use without dilut.& do not mix.with other meds.    Dosage: Adult males incl.elderly: 1 tab once dly. for 2 yrs. or
   Adults: Recomm.init.dos: 0,9 mg SC 2xdly. Pre-diab./diab.mellit:   not be prescribed   unt.progress.
   Init.0,6 mg 2xdly.with dos. incr.to 0,9 mg 2xdly aft.2 mnths.bas.on   Contraindications: Women, childr., breastfeed. mothers, lact.intol.,
   respons. & that 0,6 mg dos.well tol.  to pregnant or       concom. astemizole/cisapride/ ciclosprin.
   Consid.indiv.dos.reduct.if respons.stable. Max. urin. free cortisol.  Side effects: Hot flush., prurit., breast tendern., gynaecomast., GI
   reduct.seen by 2 mnths.of treatm. Consid.discont.if no clinic.benef.  lactating women   disturbs.incl.rect.bleed., dyspeps., dry/skin mouth, methaemaglobi-
   exper.aft.2 mnths ther.                unless the          naem., hepatit./jaund., cholestat.jaund., skin reacts.incl. epiderm.
   For tempor.dos.reduct.managem.of suspect. adverse reacts.reduc.  necrolys., sweat., hirsutism, alopec., asthen., hepat.chang.somet.
   dos.by decrements of 0,3 mg 2xdly.  anticipated benefit    sev., ang., HF, conduct. irregul. in PR & QT prolongat., dysrhythm.,
   Contraindications: Sev.hepat.impairm.(Child Pugh C).       non-specif.ECG chang., pulm./URTI, bronchit., pneumon., sepsis, bld.
   Side effects: V.common: Diarrh., naus., abdom.pain, cholelithias.,   clearly outweighs   dyscras., haemolys., angioed., weight chang., diabet., hyperglycaem.,
   hyperglycaem., diab.mellit., fatig., inj.site react. Common: Adren.   dizzin., somnol., oed., CNS effs., chills, headache, vis. disturbs.incl.
   insuffic., type 2 diab. melllit., decr.appetite, headache, vomit., upper   any potential risk   chromatops., imp.adapt./incr. light sens., hypertens., thorac./medi-
   abdom.pain, alopec., sinus bardycard., QT prolongat., vertigo, abdom.   to the foetus.  ast./psych. disords., runny nose, cough/hoarsen., shortn.of breath,
   distens., flatul., freq.bowel movem., dry mouth, asthen., malaise,   dyspn., chest tighn./wheez., sore throat, pulm. disords.e.g.fibros.,
   cholecystit., cholestas., decr. weight, imp.gluc.tol., hypoglycaem.,   pneumonit., musc./joint weakn., neuropathy, heamatur., noctur.,
   arthralg., myalg., dizzin., dysgeus., somnol., dry skin, prurit., skin ex-  decr. libido, impot., galactorrh., chest/abd./pelv. pain, fev., flu-like
   foliat., hypotens. Uncommon: Anaem., blurr. vis., abdom.discomf.,   sympt., hypersens. reacts.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page350.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page346.html">346</a>&nbsp;&nbsp;&nbsp;<a href="page347.html">347</a>&nbsp;&nbsp;&nbsp;<a href="page348.html">348</a>&nbsp;&nbsp;&nbsp;<a href="page349.html">349</a>&nbsp;&nbsp;&nbsp;<a href="page350.html">350</a>&nbsp;&nbsp;&nbsp;<a href="page351.html">351</a>&nbsp;&nbsp;&nbsp;<a href="page352.html">352</a>&nbsp;&nbsp;&nbsp;<a href="page353.html">353</a>&nbsp;&nbsp;&nbsp;<a href="page354.html">354</a>&nbsp;&nbsp;&nbsp;<a href="page355.html">355</a>&nbsp;&nbsp;&nbsp;<a href="page356.html">356</a>
             </td>
             <td width="35%"><a href="page352.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page352.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
